New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For BMY;PFE;DUF;CG;HLF;CALM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | all recent news | >>
February 26, 2015
19:28 EDTHLFHerbalife results negatively impacted by declines in U.S., Mexico, Brazil, Korea
19:25 EDTHLFHerbalife CEO Johnson says 'not happy with topline results'
Subscribe for More Information
16:22 EDTHLFHerbalife up 6% following Q4 results, guidance
16:21 EDTHLFHerbalife CEO comments on 2015 outlook
Michael Johnson, chairman and CEO stated, 2014 was a record year in terms of net sales, volume and sales leader retention. It was also a year of transition, as we continue to implement changes that we believe will create a stronger company with the ideal combination of growth and sustainability. We have seen the success of these changes in early adopter markets and remain confident that our other markets will follow a similar pattern through 2015 and beyond. Johnson continued, "Our revised guidance reflects the currency landscape faced by all global companies and the short-term volume impact of the enhancements we are making. We believe we are executing the right long-term strategy and are confident in our ability to create sustainable value for our shareholders and the millions of Herbalife members and their customers worldwide."
16:20 EDTHLFHerbalife sees FY15 free cash flow $430M-$460M
Subscribe for More Information
16:20 EDTHLFHerbalife sees FY15 CapEx $120M-$140M
16:19 EDTHLFHerbalife sees FY15 volume point growth (4.5%)-(1.5%) y/y
Subscribe for More Information
16:19 EDTHLFHerbalife sees Q1 volume point growth (8%)-(5%) y/y
Subscribe for More Information
16:18 EDTHLFHerbalife sees FY15 currency adjusted adjusted EPS $5.30-$5.70, consensus $5.08
Sees FY15 currency adjusted net sales growth (1%)-2%, consensus $4.8B.
16:17 EDTHLFHerbalife sees Q1 currency adjusted EPS $1.30-$1.40, consensus $1.30
Sees Q1 currency adjusted net sales growth (7.5%)-(4.5%), consensus $1.17B.
16:15 EDTHLFHerbalife sees FY15 adjusted EPS $4.10-$4.50, consensus $5.08
Subscribe for More Information
16:14 EDTHLFHerbalife reports Q4 adjusted EPS $1.41, consensus $1.22
Reports Q4 revenue $1.1B, consensus $1.16B.
15:30 EDTHLFNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Monster Beverage (MNST), consensus 59c... Ross Stores (ROST), consensus $1.11... Gap (GPS), consensus 74c... Autodesk (ADSK), consensus 24c... Universal Health Services (UHS), consensus $1.50... Southwestern Energy (SWN), consensus 50c... Ensco (ESV), consensus $1.36... J.C. Penney (JCP), consensus 11c... Nimble Storage (NMBL), consensus (14c)... Herbalife (HLF), consensus $1.22... Allscripts Healthcare (MDRX), consensus 9c... SBA Communications (SBAC), consensus 2c... Aruba Networks (ARUN), consensus 27c... Splunk (SPLK), consensus 4c... Air Lease (AL), consensus 61c... Ingram Micro (IM), consensus 99c... Weight Watchers (WTW), consensus 7c... Northern Oil and Gas (NOG), consensus 19c... Envision Healthcare (EVHC), consensus 36c... Infoblox (BLOX), consensus 5c... Live Nation (LYV), consensus (41c)... OmniVision (OVTI), consensus 29c... Bonanza Creek Energy (BCEI), consensus 27c.
15:23 EDTBMYBristol-Myers reports ALLY trial demonstrates 97% hepatitis C cure rates
Subscribe for More Information
13:30 EDTHLFEarnings Preview: Herbalife reporting after Soros, Post Holdings increase stakes
Subscribe for More Information
12:31 EDTPFEPfizer says CDC recommends serogroup B meningococcal vaccine for those at risk
Subscribe for More Information
08:35 EDTBMYBristol-Myers says BMS-966176 Phase IIa study met primary endpoint
Subscribe for More Information
06:11 EDTHLFStocks with implied volatility above IV index mean; ANF HLF
Stocks with implied volatility above IV index mean; Abercrombie & Fitch (ANF) 64, Herbalife (HLF) 94 according to iVolatility.
February 25, 2015
08:36 EDTBMYBristol-Myers announces data from Phase IIb BMS-663068 trial
Bristol-Myers Squibb Company announced data from a Phase IIb trial of investigational compound BMS-663068, designed as an HIV-1 attachment inhibitor, in treatment-experienced HIV-1 patients. In the study, which compared BMS-663068 to a pharmacoenhanced protease inhibitor, virologic response rates and immunologic reconstitution were similar across the BMS-663068 and Reyataz/ritonavir arms of the trial through 48 weeks. Specifically, 61-82% of BMS-663068 patients had HIV-1 RNA levels <50 c/mL, compared to 71% of Reyataz/ritonavir patients at week 48. HIV-1 RNA levels <50 c/mL typically indicate virus replication is undetectable. Treatment with BMS-663068 resulted in no dose response safety signals, no treatment discontinuations related to adverse events, and no treatment-related serious adverse events over the course of the trial. The most common AEs were headache and abdominal pain. Due to the positive results seen thus far, a Phase III clinical trial of the attachment inhibitor among heavily treatment-experienced patients began on Monday, February 23, 2015. For the purposes of the Phase III trial, heavily treatment-experienced patients are defined as individuals who can no longer formulate a viable regimen due to accumulation of drug resistance, past intolerabilities or antiretroviral contraindications. The Phase IIb study results, presented yesterday at the 22nd Conference on Retroviruses and Opportunistic Infections, highlight the novel mechanism of action of the investigational prodrug BMS-663068, which when converted into its active moiety BMS-626529, is designed to bind directly to the HIV gp120 protein, and prevents initial viral attachment to the host CD4+ T cell and entry into the host immune cell.
05:53 EDTHLFStocks with implied volatility above IV index mean; ANF HLF
Subscribe for More Information
<< 1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use